Cargando…
Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332419/ https://www.ncbi.nlm.nih.gov/pubmed/28293379 http://dx.doi.org/10.4254/wjh.v9.i6.300 |
_version_ | 1782511537480531968 |
---|---|
author | Gera, Shweta Ettel, Mark Acosta-Gonzalez, Gabriel Xu, Ruliang |
author_facet | Gera, Shweta Ettel, Mark Acosta-Gonzalez, Gabriel Xu, Ruliang |
author_sort | Gera, Shweta |
collection | PubMed |
description | Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities. |
format | Online Article Text |
id | pubmed-5332419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-53324192017-03-14 Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma Gera, Shweta Ettel, Mark Acosta-Gonzalez, Gabriel Xu, Ruliang World J Hepatol Minireviews Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities. Baishideng Publishing Group Inc 2017-02-28 2017-02-28 /pmc/articles/PMC5332419/ /pubmed/28293379 http://dx.doi.org/10.4254/wjh.v9.i6.300 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Gera, Shweta Ettel, Mark Acosta-Gonzalez, Gabriel Xu, Ruliang Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma |
title | Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma |
title_full | Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma |
title_fullStr | Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma |
title_full_unstemmed | Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma |
title_short | Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma |
title_sort | clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332419/ https://www.ncbi.nlm.nih.gov/pubmed/28293379 http://dx.doi.org/10.4254/wjh.v9.i6.300 |
work_keys_str_mv | AT gerashweta clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma AT ettelmark clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma AT acostagonzalezgabriel clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma AT xuruliang clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma |